Trials / Terminated
TerminatedNCT00452478
Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5
A Phase IV, Open-Label, Multi-Centre Trial Evaluating the Conversion From Standard Phosphate Binder Therapy to Fosrenol® in Chronic Kidney Disease Stage 5 Patients on Haemodialysis
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this research study is to see if giving Fosrenol®, a chewable tablet, to patients on haemodialysis works as well as other treatments currently used to lower blood phosphorus levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanthanum carbonate | 2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day. |
Timeline
- Start date
- 2007-05-22
- Primary completion
- 2007-12-10
- Completion
- 2007-12-10
- First posted
- 2007-03-27
- Last updated
- 2021-05-25
Locations
14 sites across 6 countries: Austria, Belgium, Denmark, Germany, Italy, Netherlands
Source: ClinicalTrials.gov record NCT00452478. Inclusion in this directory is not an endorsement.